Medline (NASDAQ:MDLN) Now Covered by Analysts at Rothschild & Co Redburn

Stock analysts at Rothschild & Co Redburn started coverage on shares of Medline (NASDAQ:MDLN) in a note issued to investors on Monday,Benzinga reports. The brokerage set a “neutral” rating and a $42.00 price target on the stock. Rothschild & Co Redburn’s target price would suggest a potential upside of 3.65% from the stock’s previous close.

A number of other analysts have also weighed in on MDLN. The Goldman Sachs Group set a $49.00 price objective on Medline and gave the stock a “buy” rating in a research report on Monday. Robert W. Baird began coverage on Medline in a research report on Monday. They issued an “outperform” rating and a $48.00 price target on the stock. Piper Sandler assumed coverage on shares of Medline in a report on Monday. They issued an “overweight” rating and a $50.00 target price on the stock. Wall Street Zen upgraded shares of Medline to a “hold” rating in a research note on Saturday. Finally, JPMorgan Chase & Co. assumed coverage on shares of Medline in a research report on Monday. They issued an “overweight” rating and a $50.00 price objective on the stock. Eighteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $47.25.

Medline Price Performance

Shares of MDLN stock opened at $40.52 on Monday. Medline has a fifty-two week low of $34.89 and a fifty-two week high of $45.50.

Insider Activity

In related news, Director Charles N. Mills purchased 2,579,310 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were purchased at an average cost of $29.00 per share, for a total transaction of $74,799,990.00. Following the purchase, the director directly owned 2,441,379 shares of the company’s stock, valued at $70,799,991. The trade was a -1,870.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of Medline stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $28.37, for a total value of $172,727,085.27. Following the sale, the insider owned 4,806,160 shares in the company, valued at $136,350,759.20. This trade represents a 55.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies started coverage with a “Buy,” highlighting Medline’s ~$25 billion supply-chain scale as a durable competitive advantage that supports growth and margin expansion. Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
• Positive Sentiment: TipRanks coverage of new sell‑side initiations (e.g., J.P. Morgan) emphasizes Medline’s prime‑vendor position, branded mix shift and margin expansion runway — factors analysts say justify a premium valuation. Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation
• Positive Sentiment: Multiple outlets report a broad set of bullish analyst initiations after the IPO (Buy/Overweight ratings and constructive price targets), which is amplifying positive sentiment and buying interest. Analysts initiate Medline with bullish ratings after blockbuster IPO
• Positive Sentiment: Media and TV coverage — including praise from commentators such as Jim Cramer — is raising retail and institutional visibility for MDLN, supporting near‑term momentum. Jim Cramer Medline: “It’s a Terrific Company”
• Neutral Sentiment: A valuation note points out shares are trading near a DCF estimate after the recent moves, suggesting limited near‑term upside unless execution or margin beats occur — a reminder that much of the positive view is already priced in. Medline (MDLN) Valuation Check As Shares Trade Near DCF Estimate After Recent Moves

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.